Literature DB >> 8883227

Hyponatremia related to medical anticancer treatment.

T Berghmans1.   

Abstract

Hyponatremia is a common potential complication in cancer patients. It can be related to anticancer medical therapy. Vincristine, vinblastine, cisplatin and cyclophosphamide are the chemotherapeutic agents most frequently associated with hyponatremia. More recently, analogs such as carboplatin and ifosfamide have also been incriminated. Hyponatremia is also associated with new immunomodulators (interferon, interleukin-2 and levamisole) and monoclonal antibodies. The mechanism by which all these drugs act on the sodium steady state is only partially known. The syndrome of inappropriate antidiuretic hormone secretion is described secondary to vinca alkaloids and cisplatin and possibly with alkylating agents. Renal salt wasting is described with platinum compounds.

Entities:  

Mesh:

Year:  1996        PMID: 8883227     DOI: 10.1007/bf01788840

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  81 in total

1.  Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion.

Authors:  B M Cantwell; M Idle; M J Millward; G Hall; M J Lind
Journal:  Ann Oncol       Date:  1990       Impact factor: 32.976

2.  Cisplatin-induced sodium and magnesium wastage.

Authors:  A Orbo; E Simonsen
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

3.  Renal salt wasting and carboplatinum.

Authors:  J Welborn; F J Meyers; L F O'Grady
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

4.  Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.

Authors:  G L Robertson; N Bhoopalam; L J Zelkowitz
Journal:  Arch Intern Med       Date:  1973-11

5.  Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level).

Authors:  R M Suskind; S W Brusilow; J Zehr
Journal:  J Pediatr       Date:  1972-07       Impact factor: 4.406

6.  [Hyponatremia in acute leukemia].

Authors:  J P Vernant; G Mouchnino; B Brun; F Reyes; M Kuentz; H Rochant; B Dreyfus
Journal:  Ann Med Interne (Paris)       Date:  1978-02

7.  Fluid and electrolyte problems in patients with advanced carcinoma.

Authors:  F J Takacs
Journal:  Med Clin North Am       Date:  1975-03       Impact factor: 5.456

8.  Water intoxication following moderate-dose intravenous cyclophosphamide.

Authors:  R B Bressler; D P Huston
Journal:  Arch Intern Med       Date:  1985-03

9.  Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption.

Authors:  Y K Kim; H S Byun; Y H Kim; J S Woo; S H Lee
Journal:  Toxicol Appl Pharmacol       Date:  1995-01       Impact factor: 4.219

10.  Inappropriate antidiuretic hormone secretion after high dose vinblastine.

Authors:  A Antony; W A Robinson; C Roy; W Pelander; R Donohue
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

View more
  16 in total

1.  Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Authors:  R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2014-08-21       Impact factor: 3.603

Review 2.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

3.  Interferon-alpha is a predisposing risk factor for carbamazepine-induced hyponatremia: A case of syndrome of inappropriate antidiuresis caused by interferon-alpha therapy.

Authors:  Midori Tanaka; Kyuzi Kamoi; Toru Takahashi
Journal:  Int J Gen Med       Date:  2008-11-30

Review 4.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Harry Raftopoulos
Journal:  Support Care Cancer       Date:  2007-08-14       Impact factor: 3.603

Review 5.  Tumor-related hyponatremia.

Authors:  Adedayo A Onitilo; Ebenezer Kio; Suhail A R Doi
Journal:  Clin Med Res       Date:  2007-12-17

6.  The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

Authors:  Fabio A B Schutz; Wanling Xie; Frede Donskov; Monica Sircar; David F McDermott; Brian I Rini; Neeraj Agarwal; Sumanta Kumar Pal; Sandy Srinivas; Christian Kollmannsberger; Scott A North; Lori A Wood; Ulka Vaishampayan; Min-Han Tan; Mary J Mackenzie; Jae Lyun Lee; Sun-Young Rha; Takeshi Yuasa; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-10-26       Impact factor: 20.096

7.  Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer.

Authors:  Seong-Bae Hwang; Hye-Yoon Lee; Hoon-Yub Kim; Eun-Sook Lee; Jeoung-Won Bae
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

8.  Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).

Authors:  Shuichi Hironaka; Yasuhiro Tsubosa; Junki Mizusawa; Takayuki Kii; Ken Kato; Takahiro Tsushima; Keisho Chin; Akihisa Tomori; Tatsuya Okuno; Toshikatsu Taniki; Takashi Ura; Hisayuki Matsushita; Takashi Kojima; Yuichiro Doki; Hitoshi Kusaba; Kazumasa Fujitani; Koichi Taira; Shiko Seki; Tsutomu Nakamura; Yuko Kitagawa
Journal:  Cancer Sci       Date:  2014-09       Impact factor: 6.716

9.  Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases.

Authors:  Michelle Baker; Maurie Markman; Jiaxin Niu
Journal:  Case Rep Oncol       Date:  2014-07-31

10.  High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy.

Authors:  Vikram Gota; Krunal Kavathiya; Kartik Doshi; Murari Gurjar; Solai E Damodaran; Vanita Noronha; Amit Joshi; Kumar Prabhash
Journal:  Cancer Manag Res       Date:  2014-06-04       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.